Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 2

2(25.0%)

8Total

Phase 1(6)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05674175Phase 1Recruiting

Co-administration of CART22-65s and huCART19 for B-ALL

Role: lead

NCT07464951Phase 1Not Yet Recruiting

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT04276870Phase 2Recruiting

Orphan Indications for CD19 Redirected Autologous T Cells

Role: lead

NCT05650749Phase 1Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Role: lead

NCT06934382Phase 1Recruiting

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Role: lead

NCT07007117Phase 1Recruiting

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Role: lead

NCT05480449Phase 1Recruiting

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Role: lead

NCT05029336Phase 2Recruiting

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Role: lead

All 8 trials loaded